Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (42420)	6/18/2003 8:53:42 PM
From: J.B.C.	Read Replies (1) \| Respond to of 57110

By far weakest internals I've seen which means we're headed for 1800 NAZ -g-. Jim #########################: The NYSE saw 135 issues rising on their charts and 50 falling. There were 5 new buy signals given and 4 new sell signals given for a net gain of 1. There were 18 Upward Reversals and 29 Downward. Nasdaq saw 238 issues rising on their charts and 115 falling. There were 16 new buy signals given and 11 new sell signals given for a net gain of 5. There were 66 Upward Reversals and 69 Downward. Optionable Stocks saw 181 issues rising on their charts and 95 falling. There were 5 new buy signals given and 10 new sell signals given for a net loss of 5. There were 43 Upward Reversals and 55 Downward.

To: Jorj X Mckie who wrote (42420)	6/18/2003 10:03:19 PM
From: orkrious	Respond to of 57110

I think it is pretty significant I wonder if this could get the bios rocking tomorrow? thestreet.com Adam Feuerstein Genentech bull call coming tomorrow 6/18/03 05:13 PM ET Tomorrow morning, UBS biotech analyst Meirav Chovav will issue a 60-page report on Genentech (DNA-NYSE) and its cancer drug Avastin, in which she will make the case for the drug being a $10 BILLION opportunity. Yes, $10 Billion!! The title of the report is "Avastin -- How Big is Bigger?" Chovav was one of the few sell-side analysts to call correctly the Avastin colon cancer trial. Since then, she's put a $100 price target on Genentech. She is the big Genentech bull. none